Trial Profile

A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Runimotamab (Primary) ; Tocilizumab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Sponsors Genentech

30 Apr 2025 Results (n=73) assessing safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity. Data cut-off date was 01Aug2024, presented at the 116th Annual Meeting of the American Association for Cancer Research.
04 Mar 2025 Planned End Date changed from 31 May 2025 to 30 Dec 2026.
04 Mar 2025 Planned primary completion date changed from 31 May 2025 to 30 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com